真人做爰48姿势视图片|少妇真人直播免费视频|日本真人做爰A片|真人裸体做爰视频|真人与拘做爰视频免费观看|真人与拘做受免费视频一

穿孔素1(PRF1)活性蛋白

Active Perforin 1 (PRF1)

FLH2; HPLH2; P1; PFP; Pore Forming Protein; Cytolysin; Lymphocyte pore-forming protein

  • 穿孔素1(PRF1)活性蛋白 產(chǎn)品包裝(模擬)
  • 穿孔素1(PRF1)活性蛋白 產(chǎn)品包裝(模擬)
  • 穿孔素1(PRF1)活性蛋白 Figure . Gene Sequencing (extract)
  • APB317Hu01.jpg Figure. SDS-PAGE
  • 穿孔素1(PRF1)活性蛋白 WB圖
  • Certificate 通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證

活性實(shí)驗(yàn)

Figure. The binding activity of PRF1 with CRT.
Perforin 1 (PRF1) is a pore forming cytolytic protein found in the granules of cytotoxic T lymphocytes (CTLs) and NK cells. Upon degranulation, perforin binds to the target cell's plasma membrane, and oligomerises in a Ca2 dependent manner to form pores on the target cell. The pore formed allows for the passive diffusion of a family of pro-apoptotic proteases, known as the granzymes, into the target cell. Besides, Calreticulin (CRT) has been identified as an interactor of PRF1, thus a binding ELISA assay was conducted to detect the interaction of recombinant human PRF1 and recombinant human CRT. Briefly, PRF1 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μL were then transferred to CRT-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-PRF1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of PRF1 and CRT was shown in Figure 1, and this effect was in a dose dependent manner.

Figure. Hemolysis activity of recombinant human PRF1.
The activity of recombinant PRF1 was measured by lysis of erythrocytes using a hemolysis assay. A general procedure is as fllows: two-fold dilute the recombinant human PRF1 with 0.9% NaCl, add 50μL a serial dilution of PRF1, 10μL 0.1M CaCl2 to each well, then add 50μL 0.25% rabbit erythrocyte (RaE) to each well and mixed gently. Add 10μL 0.9% NaCl to reaplace CaCl2 in control wells. The plate is incubated for 20 hours at 37℃, 5% CO2. The results are shown in Figure 2. It was obvious that the minimal effective concentration of PRF1 is 12.5μg/mL.
(A) 0.25% RaE tread with 12.5μg/mL PRF1 for 20h;
(B) Negative control (0.25% RaE tread with 12.5ug/mL PRF1) without CaCl2.

用法

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

儲(chǔ)存

避免反復(fù)凍融。2-8°C不超過一個(gè)月,-80°C不超過12個(gè)月。

穩(wěn)定性

熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。

相關(guān)產(chǎn)品

編號(hào) 適用物種:Homo sapiens (Human,人) 應(yīng)用(僅供研究使用,不用于臨床診斷!)
RPB317Hu02 穿孔素1(PRF1)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
APB317Hu01 穿孔素1(PRF1)活性蛋白 Cell?culture;?Activity?Assays.
RPB317Hu01 穿孔素1(PRF1)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
APB317Hu02 穿孔素1(PRF1)活性蛋白 Cell?culture;?Activity?Assays.
PAB317Hu01 穿孔素1(PRF1)多克隆抗體 WB; IHC; ICC; IP.
LAB317Hu81 穿孔素1(PRF1)多克隆抗體(異硫氰酸熒光素標(biāo)記) WB; IHC; ICC; IF.
LAB317Hu71 穿孔素1(PRF1)多克隆抗體(生物素標(biāo)記) WB; IHC; ICC.
MAB317Hu22 穿孔素1(PRF1)單克隆抗體 WB; IHC; ICC; IP.
MAB317Hu21 穿孔素1(PRF1)單克隆抗體 WB; IHC; ICC; IP.
SEB317Hu 穿孔素1(PRF1)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB317Hu 穿孔素1(PRF1)等多因子檢測試劑盒(流式熒光發(fā)光法) FLIA Kit for Antigen Detection.

參考文獻(xiàn)

雜志 參考文獻(xiàn)
Diagnostic Microbiology and Infectious Disease Granzyme B as a diagnostic marker of tuberculosis in patients with and without HIV coinfection [Pubmed:26915636]
FASEB?JOURNAL The immunoregulatory effects of CD8 T-cell–derived perforin on diet-induced nonalcoholic steatohepatitis [Pubmed: 30951375]
Theranostics A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors [Pubmed: 31695790]
Mol Immunol CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection [Pubmed: 33223223]
INVESTIGATIONAL NEW DRUGS Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors [Pubmed: 32772342]
Am J Transl Res Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma [34377237]
Nat Biomed Eng Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy [34873307]
J Exp Med Single-cell immune profiling reveals functional diversity of T cells in tuberculous pleural effusion [Pubmed:35061012]
留言咨詢
长春市| 天峨县| 海门市| 墨脱县| 通渭县| 抚顺市| 滨州市| 柳河县| 庆元县| 蕉岭县| 禹城市| 阿拉善右旗| 滦南县| 农安县| 汝州市| 合江县| 曲阳县| 昌黎县| 金坛市| 宁波市| 固镇县| 拜城县| 临汾市| 绥宁县| 沐川县| 上高县| 栾城县| 宝兴县| 托里县| 民乐县| 洛阳市| 兰州市| 定安县| 牟定县| 榆社县| 宁武县| 江门市| 特克斯县| 瑞昌市| 南木林县| 青川县|